Citizens Jmp Has Lowered Expectations for Enovis (NYSE:ENOV) Stock Price

Enovis (NYSE:ENOV) had its target price reduced by analysts at Citizens Jmp from $55.00 to $47.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price target would suggest a potential upside of 127.49% from the company’s previous close.

Several other research analysts have also recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of Enovis in a report on Wednesday. Canaccord Genuity Group decreased their price target on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, August 17th. BTIG Research lowered their price target on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Finally, UBS Group reissued a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.12.

Enovis Stock Performance

ENOV stock opened at $20.66 on Wednesday. The company has a 50-day simple moving average of $25.65 and a 200 day simple moving average of $24.27. The company has a market capitalization of $1.19 billion, a P/E ratio of -1.07 and a beta of 1.32. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a fifty-two week low of $19.14 and a fifty-two week high of $34.28.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same quarter last year, the company earned $0.79 EPS. Enovis’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have purchased 3,200 shares of company stock valued at $69,864. 2.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Enovis

Several hedge funds have recently bought and sold shares of ENOV. First National Bank of Omaha purchased a new stake in shares of Enovis in the second quarter worth approximately $1,250,000. Front Street Capital Management Inc. grew its stake in Enovis by 106.1% in the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after purchasing an additional 384,124 shares in the last quarter. Invenomic Capital Management LP grew its stake in Enovis by 6.2% in the fourth quarter. Invenomic Capital Management LP now owns 756,717 shares of the company’s stock valued at $20,159,000 after purchasing an additional 44,048 shares in the last quarter. Bernzott Capital Advisors increased its position in Enovis by 47.4% in the 1st quarter. Bernzott Capital Advisors now owns 294,125 shares of the company’s stock worth $6,691,000 after purchasing an additional 94,529 shares during the last quarter. Finally, Fifth Third Bancorp increased its position in Enovis by 50,442.8% in the 1st quarter. Fifth Third Bancorp now owns 83,901 shares of the company’s stock worth $1,909,000 after purchasing an additional 83,735 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: The proposed acquisition would add robotic automation to Enovis’ ASTRA™ enabling-technology platform, expanding its portfolio in surgical precision, workflow efficiency and patient-outcome technologies. Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics
• Positive Sentiment: Management is positioning eCential’s technology as a growth opportunity in the surgical robotics market and plans to bring its surgical robot to a broader commercial market through Enovis’ platform and distribution capabilities. Enovis to acquire eCential Robotics for €155 million
• Neutral Sentiment: The transaction remains a binding offer rather than a completed acquisition, so closing conditions, integration plans and the eventual financial contribution from eCential remain important upcoming catalysts. eCential Robotics Announces Binding Offer from Enovis
• Neutral Sentiment: Enovis is scheduled to participate in the Wells Fargo Healthcare Conference on September 8, where investors may seek additional details on the acquisition, funding and the company’s robotics strategy. Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
• Negative Sentiment: Despite the strategic appeal, investors reacted negatively to the roughly $180 million purchase commitment, apparently weighing the near-term capital deployment and execution risk against the longer-term robotics opportunity. Shares fell sharply and approached their 52-week low. Enovis drops on binding offer to acquire eCential Robotics

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.